Mon Sep 23 22:30:45 UTC 2024: ## Akero Therapeutics Insider Sells Shares, Institutional Investors Show Strong Interest

**Akero Therapeutics, Inc. (NASDAQ: AKRO)** saw insider activity on Friday, September 20th, when Catriona Yale, an insider, sold 5,500 shares of the company’s stock at an average price of $27.65. This sale generated a total value of $152,075.

Despite this insider sale, Akero Therapeutics continues to attract significant interest from institutional investors. Janus Henderson Group PLC, Price T Rowe Associates Inc. MD, Vanguard Group Inc., RTW Investments LP, and Wellington Management Group LLP have all increased their holdings in the company in recent quarters. This demonstrates strong confidence in Akero’s future prospects.

Akero Therapeutics is a company focused on developing treatments for serious metabolic diseases. Their lead product candidate, efruxifermin (EFX), is currently in Phase 3 clinical trials for the treatment of metabolic dysfunction-associated steatohepatitis (MASH).

Analyst sentiment towards Akero Therapeutics remains positive. HC Wainwright has reaffirmed a “buy” rating and issued a $50.00 price target. Wolfe Research has initiated coverage on the company with an “outperform” rating, and Cantor Fitzgerald reiterated an “overweight” rating. The overall consensus rating is “Moderate Buy” with a consensus target price of $41.13.

**Akero Therapeutics’ stock traded up $0.29 to $28.37 on Monday, with 474,393 shares changing hands.** The company currently has a market capitalization of $1.96 billion.

This news article provides a succinct overview of the recent insider activity, institutional investor interest, and analyst sentiment surrounding Akero Therapeutics. It highlights the company’s focus on developing treatments for metabolic diseases and provides key financial information for investors.

Read More